[Effect of preoperative monocyte-lymphocyte ratio on prognosis of patients with resectable esophagogastric junction cancer].
Objective:To investigate the associations between various blood test parameters including MLR (monocyte-lymphocyte ratio) and prognosis in post-operative esophagogastric junction cancer patients.Methods:We retrospectively studied the preoperative and postoperative data of 309 patients who underwent radical surgery for esophagogastric junction cancer. The relationship between MLR, neutrophil lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and overall survival (OS) was analyzed.Results:The cutoff values of MLR、NLR and PLR were 0.201, 1.697 and 96.960, respectively. The median OS was 51.4 months for all the patients in the study group (n=309). MLR in patients with esophagogastric junction carcinoma was associated with gender, depth of invasion, histological grade, TNM stage, NLR and PLR (P<0.05). PLR was associated with tumor size, TNM stage, NLR and MLR (P<0.05). NLR was associated with gender, tumor size, TNM stage, PLR and MLR (bothP<0.05). Univariate analysis showed that tumor size, depth of tumor invasion, metastasis of lymph nodes, pathological grading, nerve infiltration, lymphovascular invasion, TNM staging, PLR and MLR were associated with the median overall survival time (P<0.05). Multivariate analysis showed that TNM stage, nerve infiltration and MLR were independent prognostic predictors for patients with esophagogastric junction cancer (P<0.05), but not PLR or NLR. Setting the optimal cut-off value of the MLR in 0.201, the area under the curve was 0.603, significantly larger than that of PLR and NLR (P<0.05).Conclusions:Preoperative MLR is a very useful predictor of patients with esophagogastric junction cancer who underwent radical rescetion. Preoperative MLR> 0.201 is an independent risk factor for postoperative survival in patients with esophagogastric cancer, and PLR> 96.960 may predict a poor prognosis risk.
Oncology Center, the Third Affiliated Hospital, Soochow University, Changzhou 213001, China.
W J
WJ
Zhou
Oncology Center, the Third Affiliated Hospital, Soochow University, Changzhou 213001, China.
J
J
Wu
Oncology Center, the Third Affiliated Hospital, Soochow University, Changzhou 213001, China.
X D
XD
Li
Oncology Center, the Third Affiliated Hospital, Soochow University, Changzhou 213001, China.
Q
Q
Wang
Oncology Center, the Third Affiliated Hospital, Soochow University, Changzhou 213001, China.
X F
XF
Ni
Oncology Center, the Third Affiliated Hospital, Soochow University, Changzhou 213001, China.
J T
JT
Jiang
Oncology Center, the Third Affiliated Hospital, Soochow University, Changzhou 213001, China.
M
M
Ji
Oncology Center, the Third Affiliated Hospital, Soochow University, Changzhou 213001, China.
C P
CP
Wu
D000230:Adenocarcinoma; D000704:Analysis of Variance; D001792:Blood Platelets / Q000166:cytology; D004938:Esophageal Neoplasms / Q000097:blood* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D004943:Esophagogastric Junction / Q000473:pathology / Q000601:surgery; D006801:Humans; D007958:Leukocyte Count; D008198:Lymph Nodes; D008214:Lymphocytes / Q000166:cytology*; D009000:Monocytes / Q000166:cytology*; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D009504:Neutrophils / Q000166:cytology; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000097:blood* / Q000401:mortality* / Q000473:pathology / Q000601:surgery
Curative resection; Esophagogastric junction cancer; Monocyte/lymphocyte ratio; Prognosis; Survival